Clinical Trials | December 05, 2022
Jemperli RUBY phase III trial met its primary endpoint
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
This product is based on Osmotic Controlled Release Oral Delivery System technology
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
40,000 visitors and representatives of more than 80 countries set to visit the show
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
The only definitive way to diagnose and stage lung cancers is through biopsies
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
Subscribe To Our Newsletter & Stay Updated
